Alcohol use disorders (AUDs) are common, chronic conditions affecting more than 10% of US adults.
to increase awareness and use of pharmacotherapy for AUD. The most important benefit of this review, however, will be if it leads to more patient-centered care for AUD.
Patient-centered care and shared decision making are essential for delivery of high-quality mental health and substance use disorder treatments. 3 Shared decision making requires a dialogue between patients and clinicians aimed at (1) helping patients better understand their medical conditions and the need to make treatment decisions; (2) providing information about the benefits and adverse effects of treatment options; (3) supporting patients while they clarify their values and preferences and make a decision, even if for no treatment; and (4) providing support while patients implement their decisions. 6, 7 For patients with impaired decisional capacity due to their illness, shared decision making includes working with family, caregivers, or other people who support the patient. Patient decision aids, which provide up-to-date information on treatment options and support patient-clinician communication about patient preferences, are often used to support shared decision making and increase patient-centered care. 8 Current medical management of AUD is usually in stark contrast to concepts of patient-centered care. In the United States, patients with AUD are typically offered referral to a single type of AUD treatment-group-based, abstinenceoriented treatment programs relying on the 12-step principles of Alcoholics Anonymous (AA). Although many patients report benefit from these programs, most are not staffed by clinicians who can prescribe medications to treat AUD and most do not offer evidence-based behavioral treatments. 9 In addition to medications that improve drinking outcomes, 5 at least 4 types of one-on-one behavioral treatments for AUD are effective: cognitive behavioral therapy, motivational enhancement therapy, behavioral couples therapy, and 12-step facilitation. 10,11 Moreover, no single behavioral treatment is superior to all others. This is exactly the type of situation when shared decision making is most valuable. 7 However, many health care professionals do not realize there are treatment options for AUDs. As a result, most patients are offered referral to a single treatment, ie, programs based on 12-step principles, without consideration of patient preferences. The review by Jonas and colleagues 5 provides critical information about the efficacy and adverse effects of AUD pharmacotherapy needed for shared decision making and patient decision aids. The authors evaluated 122 randomized trials and 1 cohort study (total 22 803 participants). Most of the studies assessed acamprosate (27 studies, n = 7519), naltrexone (53 studies, n = 9140), or both, which are approved by the US Food and Drug Administration (FDA) for the treatment of AUD. Jonas and colleagues report that the efficacy of the oldest and best known FDA-approved medication for AUD-disulfiram-was not supported by randomized placebo-controlled trials, whereas 4 medications-naltrexone, acamprosate, topiramate, and nalmefene-improved drinking outcomes. Most studies evaluated AUD medications when added to repeated behavioral interventions in patients who were abstaining when the medication was initiated. Mimicking the behavioral interventions used in these studies in routine clinical practice could prove challenging. For example, one of the simplest behavioral interventions required 9 visits over 16 weeks, 5 more frequent contacts than are typically offered in primary care management of other common medical and psychiatric conditions. 12 Future research is needed on the efficacy of medications for AUD when patients want to reduce drinking but do not have a goal of abstaining and to determine whether medications have efficacy when provided without frequent behavioral interventions. Shared decision making for AUD can be integrated into primary care. Primary care clinicians should assess AUD severity, medical and psychiatric comorbidities, reasons patients may or may not want to change their drinking, and whether they want help doing so. When establishing the diagnosis of AUD, it is important to note that AUD is no longer divided into alcohol abuse and dependence but is now recognized as a single continuum. The new Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) diagnostic criteria for AUD rely on a count of 11 criteria, with severity assessed based on the number of criteria a patient meets: mild (2-3), moderate (4) (5) , and severe (6-11) AUDs. 13, 14 Clinicians and patients should discuss ambivalence toward change; patient goals (eg, abstinence vs decreasing drinking vs no change); preference for groupbased, one-on-one, or medication treatments or some combination; and differences in the privacy and cost of different treatments. Some patients may prefer the privacy of mutual help groups or community treatment programs that are not documented in electronic health records. Patients with mild AUD (2-3 criteria) can be offered behavioral therapies, mutual help (eg, AA), and usual AUD treatment programs. Patients meeting 4 or more criteria can be offered medications in addition to behavioral therapies. Those who are not yet interested in changing might be willing to engage in counseling aimed at helping them consider the effects of drinking on their lives and health (eg, motivational enhancement therapy). Patient decision aids can support shared decision making about AUD treatment. Patient-centered management of AUD will need to be integrated into both primary care and general mental health care. Patients with uncomplicated AUD can be managed in primary care by integrated primary care mental health teams, whereas patients with more complex AUD or those experiencing severe effects might benefit from mental health specialty care. However, providing shared decision making and caring for patients with AUD as part of primary or mental health care will require increased clinical capacity. Innovative new systems of team-based care for AUD 15 will be needed to meet the demands of engaging patients in AUD care, assessing the severity of their AUD and comorbidity, offering them evidencebased treatments, and monitoring response to treatment.
Although primary care and mental health clinicians will eventually share in the management of AUD, general mental health clinicians should take the lead in incorporating evidence-based AUD treatments into their care. This will require support from addiction medicine colleagues because many general mental health clinicians do not currently provide treatment for AUD. However, with support they can offer both medications and effective behavioral therapies for AUD and promote integration of AUD care into primary care settings. Moreover, primary care clinicians might be reluctant to provide care for AUD if their mental health colleagues are not yet comfortable managing AUD.
Treatment of AUD is considered an essential health benefit under health care reform. More patients with AUDs will have insurance, which could increase their access to evidencebased treatments for AUDs. 16 The article by Jonas and colleagues 5 should encourage patients and their clinicians to engage in shared decision making about AUD treatment options. By identifying 4 effective medications for AUD, the authors highlight treatment options for a common medical condition for which patient-centered care is not currently the norm. Patients with AUDs should be offered options, including medications, evidence-based behavioral treatments, and mutual support for recovery. Moreover, patients should expect shared decision making about the best options for them.
